Bastidas, Adrianade la Serna, JavierEl Idrissi, MohamedOostvogels, LidiaQuittet, PhilippeLópez-Jiménez, JavierVural, FilizPohlreich, DavidZuckerman, TsilaIssa, Nicolas CGaidano, GianlucaLee, Je-JungAbhyankar, SunilSolano, CarlosPerez de Oteyza, JaimeSatlin, Michael JSchwartz, StefanCampins, MagdaRocci, AlbertoVallejo Llamas, CarlosLee, Dong-GunTan, Sen MuiJohnston, Anna MGrigg, AndrewBoeckh, Michael JCampora, LauraLopez-Fauqued, MartaHeineman, Thomas CStadtmauer, Edward ASullivan, Keith MZOE-HSCT Study Group Collaborators2025-01-072025-01-072019https://hdl.handle.net/10668/28445Herpes zoster, a frequent complication following autologous hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. A nonlive adjuvanted recombinant zoster vaccine has been developed to prevent posttransplantation zoster. To assess the efficacy and adverse event profile of the recombinant zoster vaccine in immunocompromised autologous HSCT recipients. Phase 3, randomized, observer-blinded study conducted in 167 centers in 28 countries between July 13, 2012, and February 1, 2017, among 1846 patients aged 18 years or older who had undergone recent autologous HSCT. Participants were randomized to receive 2 doses of either recombinant zoster vaccine (n = 922) or placebo (n = 924) administered into the deltoid muscle; the first dose was given 50 to 70 days after transplantation and the second dose 1 to 2 months thereafter. The primary end point was occurrence of confirmed herpes zoster cases. Among 1846 autologous HSCT recipients (mean age, 55 years; 688 [37%] women) who received 1 vaccine or placebo dose, 1735 (94%) received a second dose and 1366 (74%) completed the study. During the 21-month median follow-up, at least 1 herpes zoster episode was confirmed in 49 vaccine and 135 placebo recipients (incidence, 30 and 94 per 1000 person-years, respectively), an incidence rate ratio (IRR) of 0.32 (95% CI, 0.22-0.44; P  Among adults who had undergone autologous HSCT, a 2-dose course of recombinant zoster vaccine compared with placebo significantly reduced the incidence of herpes zoster over a median follow-up of 21 months. ClinicalTrials.gov Identifier: NCT01610414.enAdjuvants, ImmunologicAdultFemaleFollow-Up StudiesHematopoietic Stem Cell TransplantationHerpes ZosterHerpes Zoster VaccineHospitalizationHumansImmunocompromised HostIncidenceInjections, IntramuscularMaleMiddle AgedNeuralgia, PostherpeticProportional Hazards ModelsSingle-Blind MethodTransplantation, AutologousVaccines, Syntheticresearch article31287523open access10.1001/jama.2019.90531538-3598PMC6618796https://jamanetwork.com/journals/jama/articlepdf/2737683/jama_bastidas_2019_oi_190068.pdf